Homebiotech

biotech

biotech

‘Positive trends’ from phase 2 amyotrophic lateral sclerosis trial

Jim Cornall - September 17, 2026

biotech

Successful results from trial of first-in-class Parkinson’s disease peptide

Jim Cornall - September 17, 2026

biotech

Researchers uncover how neurons deliver RNA where it is needed

Jim Cornall - September 17, 2026

biotech

Revvity to acquire Human Cell Design

Jim Cornall - September 16, 2026

biotech

Potential of enzymatic single-stranded DNA for non-viral gene editing

Jim Cornall - November 26, 2025

biotech

The next era of CGT

Jim Cornall - November 25, 2025

biotech

FDA approves PADCEV plus Keytruda for certain patients with bladder cancer

Jim Cornall - November 25, 2025

biotech

‘Groundbreaking’ rapid diagnostic test for prostate cancer

Jim Cornall - November 25, 2025

biotech

Breakthrough in cancer immunotherapy using marine bacteria

Jim Cornall - November 24, 2025

biotech

Trial results could shorten TB treatment time

Jim Cornall - November 24, 2025

biotech

Customised cells to fight brain cancer

Jim Cornall - November 24, 2025

AI

Base to Base biotech podcast 36: Gothenburg, Charcot-Marie-Tooth disease and Ultrasound AI

Jim Cornall - November 21, 2025

1...606162...100 Page 61 of 100

Stay Connected

- Advertisement -

spot_img

Latest Articles

biotech

‘Positive trends’ from phase 2 amyotrophic lateral sclerosis trial

Jim Cornall - September 17, 2026 0

Axoltis Pharma has announced topline results of SEALS, its phase 2 clinical trial evaluating the effect of NX210c in patients with amyotrophic lateral sclerosis...

Successful results from trial of first-in-class Parkinson’s disease peptide

biotech Jim Cornall - September 17, 2026 0

Researchers uncover how neurons deliver RNA where it is needed

biotech Jim Cornall - September 17, 2026 0

Revvity to acquire Human Cell Design

biotech Jim Cornall - September 16, 2026 0

Engineered immune cells trial to fight colorectal cancer approved

biotech Jim Cornall - September 16, 2026 0